Literature DB >> 9713855

Fifty year follow-up of a patient with central core disease shows slow but definite progression.

P J Lamont1, V Dubowitz, D N Landon, M Davis, J A Morgan-Hughes.   

Abstract

The follow-up of a patient with central core disease (CCD) over 50 years showed that although initially the condition was moderately non-progressive, progression of a significant degree did eventually occur. Histopathological and electron microscopic data were available from muscle biopsies carried out at the ages of 19 and 55 years, and show a marked predominance of type 1 fibres with central cores in most fibres at both ages. The four mutations within the RYR1 gene described in association with CCD and three of the more common malignant hyperthermia-associated mutations within RYR1 were not present.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9713855     DOI: 10.1016/s0960-8966(98)00043-1

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  9 in total

1.  Progressive scoliosis in central core disease.

Authors:  Kirsten D Mertz; Bernhard Jost; Markus Glatzel; Kan Min
Journal:  Eur Spine J       Date:  2005-05-31       Impact factor: 3.134

Review 2.  Respiratory involvement in inherited primary muscle conditions.

Authors:  N Shahrizaila; W J M Kinnear; A J Wills
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-10       Impact factor: 10.154

3.  Congenital myopathies: Natural history of a large pediatric cohort.

Authors:  Irene Colombo; Mariacristina Scoto; Adnan Y Manzur; Stephanie A Robb; Lorenzo Maggi; Vasantha Gowda; Thomas Cullup; Michael Yau; Rahul Phadke; Caroline Sewry; Heinz Jungbluth; Francesco Muntoni
Journal:  Neurology       Date:  2014-11-26       Impact factor: 9.910

4.  The I4895T mutation in the type 1 ryanodine receptor induces fiber-type specific alterations in skeletal muscle that mimic premature aging.

Authors:  Simona Boncompagni; Ryan E Loy; Robert T Dirksen; Clara Franzini-Armstrong
Journal:  Aging Cell       Date:  2010-10-21       Impact factor: 9.304

Review 5.  Ryanodine receptor 1-related disorders: an historical perspective and proposal for a unified nomenclature.

Authors:  Tokunbor A Lawal; Joshua J Todd; Jessica W Witherspoon; Carsten G Bönnemann; James J Dowling; Susan L Hamilton; Katherine G Meilleur; Robert T Dirksen
Journal:  Skelet Muscle       Date:  2020-11-16       Impact factor: 4.912

6.  A double mutation of the ryanodine receptor type 1 gene in a malignant hyperthermia family with multiminicore myopathy.

Authors:  Seul-Ki Jeong; Dong-Chan Kim; Yong-Gon Cho; Il-Nam Sunwoo; Dal-Sik Kim
Journal:  J Clin Neurol       Date:  2008-09-30       Impact factor: 3.077

Review 7.  Central core disease.

Authors:  Heinz Jungbluth
Journal:  Orphanet J Rare Dis       Date:  2007-05-15       Impact factor: 4.123

8.  Novel Variants in Individuals with RYR1-Related Congenital Myopathies: Genetic, Laboratory, and Clinical Findings.

Authors:  Joshua J Todd; Muslima S Razaqyar; Jessica W Witherspoon; Tokunbor A Lawal; Ami Mankodi; Irene C Chrismer; Carolyn Allen; Mary D Meyer; Anna Kuo; Monique S Shelton; Kim Amburgey; Dmitriy Niyazov; Pierre Fequiere; Carsten G Bönnemann; James J Dowling; Katherine G Meilleur
Journal:  Front Neurol       Date:  2018-03-05       Impact factor: 4.003

9.  Randomized controlled trial of N-acetylcysteine therapy for RYR1-related myopathies.

Authors:  Joshua J Todd; Tokunbor A Lawal; Jessica W Witherspoon; Irene C Chrismer; Muslima S Razaqyar; Monal Punjabi; Jeffrey S Elliott; Fatoumata Tounkara; Anna Kuo; Monique O Shelton; Carolyn Allen; Mary M Cosgrove; Melody Linton; Darren Michael; Minal S Jain; Melissa Waite; Bart Drinkard; Paul G Wakim; James J Dowling; Carsten G Bönnemann; Magalie Emile-Backer; Katherine G Meilleur
Journal:  Neurology       Date:  2020-01-15       Impact factor: 9.910

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.